Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
China Resources Pharmaceutical Group has disclosed unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary, China Resources Boya Bio-pharmaceutical, which it controls with around 41.79% of the voting rights. The announcement highlights Boya’s role as a consolidated subsidiary within the wider group’s pharmaceutical operations, while noting that these figures do not provide a full picture of the group’s overall financial condition.
For the three months ended 31 March 2026, CR Boya reported revenue of RMB321.1 million and net profit of RMB30.0 million, both sharply down from the same period in 2025. The company also recorded a significant net decrease in cash and cash equivalents, despite maintaining solid owner’s equity of about RMB7.46 billion and reduced total liabilities, and shareholders are cautioned not to rely solely on this unaudited data when assessing the parent company’s securities.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated healthcare conglomerate with a diversified portfolio across pharmaceuticals and related medical businesses. Through its subsidiary China Resources Boya Bio-pharmaceutical Group, listed on the Shenzhen Stock Exchange, the group operates in the biopharmaceutical segment, focusing on specialized drug products and leveraging significant voting control despite holding less than one-third of Boya’s share capital.
Average Trading Volume: 18,740,562
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.69B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.